The first-line treatment for interstitial lung disease (ILD) varies depending on the underlying cause.
Here's a breakdown:
First-Line Treatment Options for ILD
| Condition | First-Line Treatment |
|---|---|
| Idiopathic Pulmonary Fibrosis (IPF) | Nintedanib or Pirfenidone |
| ILD due to Connective Tissue Disease | Mycophenolate Mofetil |
Understanding the Treatment Approaches
- Idiopathic Pulmonary Fibrosis (IPF): IPF is a specific type of ILD with an unknown cause. The primary aim of treatment here is to slow the progression of the disease.
- Nintedanib and pirfenidone are antifibrotic medications.
- These drugs have been shown to reduce the decline in lung function and slow down the course of the disease.
- ILD due to Connective Tissue Disease: In these cases, the ILD is a consequence of an underlying autoimmune disorder like rheumatoid arthritis, scleroderma, or lupus.
- Mycophenolate mofetil is an immunosuppressant.
- It helps to control the immune response that is causing the lung inflammation and damage.
Reference
"Interstitial lung disease typically presents with dyspnea on exertion and can progress to respiratory failure. First-line therapy is nintedanib or pirfenidone for IPF and mycophenolate mofetil for ILD due to connective tissue disease." - Referenced on 22-Apr-2024
It is important to note that the specific treatment plan will be tailored to each individual case by a healthcare professional.
